Pliant Therapeutics, Inc.
Clinical trials sponsored by Pliant Therapeutics, Inc., explained in plain language.
-
New drug shows promise in slowing deadly lung scarring
Disease control CompletedThis study tested whether a new drug called PLN-74809 could reduce the buildup of scar tissue in the lungs of people with idiopathic pulmonary fibrosis (IPF). Ten participants took either the drug or a placebo pill daily for 12 weeks. Researchers used special PET/MRI scans to mea…
Phase: PHASE2 • Sponsor: Pliant Therapeutics, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New drug trial targets scarring in rare liver disease
Disease control CompletedThis study tested the safety and correct dosage of an experimental drug called PLN-74809 in people with primary sclerosing cholangitis (PSC), a rare disease that scars the liver's bile ducts. 121 participants received either the drug or a placebo for 12 to 48 weeks to see how the…
Phase: PHASE2 • Sponsor: Pliant Therapeutics, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC